Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Yan Xu, M.D.
- Phone Number: +86 18621080996
- Email: drxuyan_2004@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Recruiting
- Shanghai Eye Diseases Prevention & Treatment Center
-
Contact:
- Haidong Zou, M.D.
- Phone Number: +86 13311986528
- Email: zouhaidong@sjtu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6 to 12 years old;
- Both eyes are in line with the diagnosis of myopic refractive error and 0.25D < myopia spherical lens <4.00D after mydriasis, astigmatism <2.00D, binocular anisometropia <3.00D, and the best corrected distance vision is at least 0.8, myopia The force is at least 0.8;
- Visual function: Timus≤100 seconds, exophoria <5△, accommodation amplitude (AMP) ≥ age-related minimum accommodation amplitude value (minimum accommodation amplitude=15-0.25×age);
- No contraindications for atropine treatment such as acute eye inflammation, dry eye, keratoconus, diabetes, etc.;
- The written informed consent of the guardian and the child himself.
Exclusion Criteria:
- History of photosensitivity, glaucoma, blue eye syndrome, ocular hypertension, fundus macular lesions or damage;
- Corneal curvature examination, the average K value of the anterior surface of the cornea is ≥45;
- Patients with ocular trauma, oblique or surgical eyes, atopic keratoconjunctivitis and other chronic eye diseases;
- Those with previous ophthalmia, severe angular, conjunctival infection and other eye diseases;
- Patients with neurological diseases and allergic or contraindications to atropine or other therapeutic drugs;
- Received other treatments to control the development of myopia in the past, such as the use of anticholinergic drugs such as atropine within 3 months, or participated in other relevant researchers such as functional frame mirrors and multifocal flexible mirrors;
- Other circumstances judged by the investigator to be unsuitable to participate in the research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1% atropine 5+3
Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct used for 5 consecutive nights in the first week of each month, one night per week in the 2nd, 3rd, and 4th weeks; after 3 months of monocular application, change to the contralateral eye Total treatment time 1 year
|
A method for myopia control using high-concentration atropine
|
|
Placebo Comparator: 1% atropine weekly
Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct once a week in both eyes Total treatment time 1 year
|
A method for myopia control using high-concentration atropine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
spherical equivalent
Time Frame: Before atropine treatment
|
spherical equivalent(SE),Diopter(D), measured by subjective optometry
|
Before atropine treatment
|
|
spherical equivalent
Time Frame: 1months after treatment
|
spherical equivalent(SE),Diopter(D), measured by subjective optometry
|
1months after treatment
|
|
spherical equivalent
Time Frame: 3months after treatment
|
spherical equivalent(SE),Diopter(D), measured by subjective optometry
|
3months after treatment
|
|
spherical equivalent
Time Frame: 6months after treatment
|
spherical equivalent(SE),Diopter(D), measured by subjective optometry
|
6months after treatment
|
|
spherical equivalent
Time Frame: 9months after treatment
|
spherical equivalent(SE),Diopter(D), measured by subjective optometry
|
9months after treatment
|
|
spherical equivalent
Time Frame: 12months after treatment
|
spherical equivalent(SE),Diopter(D), measured by subjective optometry
|
12months after treatment
|
|
axial length
Time Frame: Before atropine treatment
|
axial length(AL), millimeter(mm), measured by IOL master
|
Before atropine treatment
|
|
axial length
Time Frame: 1months after treatment
|
axial length(AL), millimeter(mm), measured by IOL master
|
1months after treatment
|
|
axial length
Time Frame: 3months after treatment
|
axial length(AL), millimeter(mm), measured by IOL master
|
3months after treatment
|
|
axial length
Time Frame: 6months after treatment
|
axial length(AL), millimeter(mm), measured by IOL master
|
6months after treatment
|
|
axial length
Time Frame: 9months after treatment
|
axial length(AL), millimeter(mm), measured by IOL master
|
9months after treatment
|
|
axial length
Time Frame: 12months after treatment
|
axial length(AL), millimeter(mm), measured by IOL master
|
12months after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
accommodation amplitude
Time Frame: Before atropine treatment
|
Accommodation amplitude is measured by the amount of diopter change as the target is moved closer, diopter(D)
|
Before atropine treatment
|
|
accommodation amplitude
Time Frame: 1months after treatment
|
Accommodation amplitude is measured by the amount of diopter change as the target is moved closer, diopter(D)
|
1months after treatment
|
|
accommodation amplitude
Time Frame: 3months after treatment
|
Accommodation amplitude is measured by the amount of diopter change as the target is moved closer, diopter(D)
|
3months after treatment
|
|
accommodation amplitude
Time Frame: 6months after treatment
|
Accommodation amplitude is measured by the amount of diopter change as the target is moved closer, diopter(D)
|
6months after treatment
|
|
accommodation amplitude
Time Frame: 9months after treatment
|
Accommodation amplitude is measured by the amount of diopter change as the target is moved closer, diopter(D)
|
9months after treatment
|
|
accommodation amplitude
Time Frame: 12months after treatment
|
Accommodation amplitude is measured by the amount of diopter change as the target is moved closer, diopter(D)
|
12months after treatment
|
|
amount of phoria
Time Frame: Before atropine treatment
|
measured by Von-Graefe method, degree(°)
|
Before atropine treatment
|
|
amount of phoria
Time Frame: 1months after treatment
|
measured by Von-Graefe method, degree(°)
|
1months after treatment
|
|
amount of phoria
Time Frame: 3months after treatment
|
measured by Von-Graefe method, degree(°)
|
3months after treatment
|
|
amount of phoria
Time Frame: 6months after treatment
|
measured by Von-Graefe method, degree(°)
|
6months after treatment
|
|
amount of phoria
Time Frame: 9months after treatment
|
measured by Von-Graefe method, degree(°)
|
9months after treatment
|
|
amount of phoria
Time Frame: 12months after treatment
|
measured by Von-Graefe method, degree(°)
|
12months after treatment
|
|
binocular vision function
Time Frame: Before atropine treatment
|
measured by Titmus method, second
|
Before atropine treatment
|
|
binocular vision function
Time Frame: 1months after treatment
|
measured by Titmus method, second
|
1months after treatment
|
|
binocular vision function
Time Frame: 3months after treatment
|
measured by Titmus method, second
|
3months after treatment
|
|
binocular vision function
Time Frame: 6months after treatment
|
measured by Titmus method, second
|
6months after treatment
|
|
binocular vision function
Time Frame: 9months after treatment
|
measured by Titmus method, second
|
9months after treatment
|
|
binocular vision function
Time Frame: 12months after treatment
|
measured by Titmus method, second
|
12months after treatment
|
|
photophobia
Time Frame: 1months after treatment
|
the prevalence of photophobia known from Atropine Use and Adverse Reactions Questionnaire
|
1months after treatment
|
|
photophobia
Time Frame: 3months after treatment
|
the prevalence of photophobia known from Atropine Use and Adverse Reactions Questionnaire
|
3months after treatment
|
|
photophobia
Time Frame: 6months after treatment
|
the prevalence of photophobia known from Atropine Use and Adverse Reactions Questionnaire
|
6months after treatment
|
|
photophobia
Time Frame: 9months after treatment
|
the prevalence of photophobia known from Atropine Use and Adverse Reactions Questionnaire
|
9months after treatment
|
|
photophobia
Time Frame: 12months after treatment
|
the prevalence of photophobia known from Atropine Use and Adverse Reactions Questionnaire
|
12months after treatment
|
|
blurred vision
Time Frame: 1months after treatment
|
the prevalence of blurred vision known from Atropine Use and Adverse Reactions Questionnaire
|
1months after treatment
|
|
blurred vision
Time Frame: 3months after treatment
|
the prevalence of blurred vision known from Atropine Use and Adverse Reactions Questionnaire
|
3months after treatment
|
|
blurred vision
Time Frame: 6months after treatment
|
the prevalence of blurred vision known from Atropine Use and Adverse Reactions Questionnaire
|
6months after treatment
|
|
blurred vision
Time Frame: 9months after treatment
|
the prevalence of blurred vision known from Atropine Use and Adverse Reactions Questionnaire
|
9months after treatment
|
|
blurred vision
Time Frame: 12months after treatment
|
the prevalence of blurred vision known from Atropine Use and Adverse Reactions Questionnaire
|
12months after treatment
|
|
Other discomfort
Time Frame: 1months after treatment
|
Other discomfort reported by the patient but not included in the Atropine Use and Adverse Reactions Questionnaire
|
1months after treatment
|
|
Other discomfort
Time Frame: 3months after treatment
|
Other discomfort reported by the patient but not included in the Atropine Use and Adverse Reactions Questionnaire
|
3months after treatment
|
|
Other discomfort
Time Frame: 6months after treatment
|
Other discomfort reported by the patient but not included in the Atropine Use and Adverse Reactions Questionnaire
|
6months after treatment
|
|
Other discomfort
Time Frame: 9months after treatment
|
Other discomfort reported by the patient but not included in the Atropine Use and Adverse Reactions Questionnaire
|
9months after treatment
|
|
Other discomfort
Time Frame: 12months after treatment
|
Other discomfort reported by the patient but not included in the Atropine Use and Adverse Reactions Questionnaire
|
12months after treatment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
lens thickness
Time Frame: Before atropine treatment
|
lens thickness(LT), millimeter(mm), measured by IOL master
|
Before atropine treatment
|
|
lens thickness
Time Frame: 1months after treatment
|
lens thickness(LT), millimeter(mm), measured by IOL master
|
1months after treatment
|
|
lens thickness
Time Frame: 3months after treatment
|
lens thickness(LT), millimeter(mm), measured by IOL master
|
3months after treatment
|
|
lens thickness
Time Frame: 6months after treatment
|
lens thickness(LT), millimeter(mm), measured by IOL master
|
6months after treatment
|
|
lens thickness
Time Frame: 9months after treatment
|
lens thickness(LT), millimeter(mm), measured by IOL master
|
9months after treatment
|
|
lens thickness
Time Frame: 12months after treatment
|
lens thickness(LT), millimeter(mm), measured by IOL master
|
12months after treatment
|
|
lens power
Time Frame: Before atropine treatment
|
lens power(LP), diopter(D), calculated by Bennett formula
|
Before atropine treatment
|
|
lens power
Time Frame: 1months after treatment
|
lens power(LP), diopter(D), calculated by Bennett formula
|
1months after treatment
|
|
lens power
Time Frame: 3months after treatment
|
lens power(LP), diopter(D), calculated by Bennett formula
|
3months after treatment
|
|
lens power
Time Frame: 6months after treatment
|
lens power(LP), diopter(D), calculated by Bennett formula
|
6months after treatment
|
|
lens power
Time Frame: 9months after treatment
|
lens power(LP), diopter(D), calculated by Bennett formula
|
9months after treatment
|
|
lens power
Time Frame: 12months after treatment
|
lens power(LP), diopter(D), calculated by Bennett formula
|
12months after treatment
|
|
anterior chamber depth
Time Frame: Before atropine treatment
|
anterior chamber depth(ACD), millimeter(mm), measured by IOL master
|
Before atropine treatment
|
|
anterior chamber depth
Time Frame: 1months after treatment
|
anterior chamber depth(ACD), millimeter(mm), measured by IOL master
|
1months after treatment
|
|
anterior chamber depth
Time Frame: 3months after treatment
|
anterior chamber depth(ACD), millimeter(mm), measured by IOL master
|
3months after treatment
|
|
anterior chamber depth
Time Frame: 6months after treatment
|
anterior chamber depth(ACD), millimeter(mm), measured by IOL master
|
6months after treatment
|
|
anterior chamber depth
Time Frame: 9months after treatment
|
anterior chamber depth(ACD), millimeter(mm), measured by IOL master
|
9months after treatment
|
|
anterior chamber depth
Time Frame: 12months after treatment
|
anterior chamber depth(ACD), millimeter(mm), measured by IOL master
|
12months after treatment
|
|
corneal power
Time Frame: Before atropine treatment
|
corneal power, diopter(D), measured by IOL master
|
Before atropine treatment
|
|
corneal power
Time Frame: 1months after treatment
|
corneal power, diopter(D), measured by IOL master
|
1months after treatment
|
|
corneal power
Time Frame: 3months after treatment
|
corneal power, diopter(D), measured by IOL master
|
3months after treatment
|
|
corneal power
Time Frame: 6months after treatment
|
corneal power, diopter(D), measured by IOL master
|
6months after treatment
|
|
corneal power
Time Frame: 9months after treatment
|
corneal power, diopter(D), measured by IOL master
|
9months after treatment
|
|
corneal power
Time Frame: 12months after treatment
|
corneal power, diopter(D), measured by IOL master
|
12months after treatment
|
|
central corneal thickness
Time Frame: Before atropine treatment
|
central corneal thickness(CTC), micron(um), measured by IOL master
|
Before atropine treatment
|
|
central corneal thickness
Time Frame: 1months after treatment
|
central corneal thickness(CTC), micron(um), measured by IOL master
|
1months after treatment
|
|
central corneal thickness
Time Frame: 3months after treatment
|
central corneal thickness(CTC), micron(um), measured by IOL master
|
3months after treatment
|
|
central corneal thickness
Time Frame: 6months after treatment
|
central corneal thickness(CTC), micron(um), measured by IOL master
|
6months after treatment
|
|
central corneal thickness
Time Frame: 9months after treatment
|
central corneal thickness(CTC), micron(um), measured by IOL master
|
9months after treatment
|
|
central corneal thickness
Time Frame: 12months after treatment
|
central corneal thickness(CTC), micron(um), measured by IOL master
|
12months after treatment
|
|
retinal thickness
Time Frame: Before atropine treatment
|
retina thickness, microns(um), measured by SSOCT
|
Before atropine treatment
|
|
retinal thickness
Time Frame: 1months after treatment
|
retina thickness, microns(um), measured by SSOCT
|
1months after treatment
|
|
retinal thickness
Time Frame: 3months after treatment
|
retina thickness, microns(um), measured by SSOCT
|
3months after treatment
|
|
retinal thickness
Time Frame: 6months after treatment
|
retina thickness, microns(um), measured by SSOCT
|
6months after treatment
|
|
retinal thickness
Time Frame: 9months after treatment
|
retina thickness, microns(um), measured by SSOCT
|
9months after treatment
|
|
retinal thickness
Time Frame: 12months after treatment
|
retina thickness, microns(um), measured by SSOCT
|
12months after treatment
|
|
choroidal thickness
Time Frame: Before atropine treatment
|
choroidal thickness, microns(um), measured by SSOCT
|
Before atropine treatment
|
|
choroidal thickness
Time Frame: 1months after treatment
|
choroidal thickness, microns(um), measured by SSOCT
|
1months after treatment
|
|
choroidal thickness
Time Frame: 3months after treatment
|
choroidal thickness, microns(um), measured by SSOCT
|
3months after treatment
|
|
choroidal thickness
Time Frame: 6months after treatment
|
choroidal thickness, microns(um), measured by SSOCT
|
6months after treatment
|
|
choroidal thickness
Time Frame: 9months after treatment
|
choroidal thickness, microns(um), measured by SSOCT
|
9months after treatment
|
|
choroidal thickness
Time Frame: 12months after treatment
|
choroidal thickness, microns(um), measured by SSOCT
|
12months after treatment
|
|
ciliary muscle thickness
Time Frame: Before atropine treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
Before atropine treatment
|
|
ciliary muscle thickness
Time Frame: 1months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
1months after treatment
|
|
ciliary muscle thickness
Time Frame: 3months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
3months after treatment
|
|
ciliary muscle thickness
Time Frame: 6months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
6months after treatment
|
|
ciliary muscle thickness
Time Frame: 9months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
9months after treatment
|
|
ciliary muscle thickness
Time Frame: 12months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
12months after treatment
|
|
the distance between ciliary muscle apex and scleral spur
Time Frame: Before atropine treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
Before atropine treatment
|
|
the distance between ciliary muscle apex and scleral spur
Time Frame: 1months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
1months after treatment
|
|
the distance between ciliary muscle apex and scleral spur
Time Frame: 3months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
3months after treatment
|
|
the distance between ciliary muscle apex and scleral spur
Time Frame: 6months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
6months after treatment
|
|
the distance between ciliary muscle apex and scleral spur
Time Frame: 9months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
9months after treatment
|
|
the distance between ciliary muscle apex and scleral spur
Time Frame: 12months after treatment
|
ciliary muscle thickness, microns(um), photographed by ASOCT and measured by semiautomatic software
|
12months after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yan Xu, M.D., Shanghai Eye Diseases Prevention Treatment Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Refractive Errors
- Myopia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Mydriatics
- Atropine
Other Study ID Numbers
Other Study ID Numbers
- 2021SQ001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.